Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a large growth in short interest in May. As of May 15th, there was short interest totaling 112,008 shares, a growth of 827.2% from the April 30th total of 12,080 shares. Based on an average daily volume of 927 shares, the short-interest ratio is currently 120.8 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating on shares of Hansa Biopharma AB (publ) in a report on Thursday, February 12th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hansa Biopharma AB (publ) has an average rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

Shares of HNSBF opened at $2.90 on Friday. Hansa Biopharma AB has a 52-week low of $2.90 and a 52-week high of $2.90. The stock has a fifty day simple moving average of $2.90 and a two-hundred day simple moving average of $2.91.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.